CPT code 82638: Dibucaine number, enzyme phenotype2026 Medicare lab fee · Clinical Laboratory Fee Schedule

Measures how dibucaine inhibits plasma cholinesterase to identify enzyme variants associated with prolonged paralysis after certain anesthetic drugs.

CMS CLFS 2026 Q4Effective Oct 1, 2026Same amount nationwide47 Medicare services in 2024

Medicare pays $12.25 for 82638 under the 2026 Clinical Laboratory Fee Schedule: one national amount, the same in every state and setting.

Medicare lab fee · CLFS 2026 Q4

National CLFS amount

$12.25

In effect since Jan 1, 2026. The same amount in every state, payment locality and setting.

Geographic adjustment
None
Office vs facility
Same
Since 2020
Unchanged
CMS updates
Quarterly

Medicare pays the lesser of the lab’s charge and this amount. Patients usually owe no Part B deductible or coinsurance for covered clinical lab tests.

On this page 7 sections
  1. Medicare lab fee
  2. What 82638 covers
  3. How it’s paid
  4. Amount history
  5. Similar tests
  6. Billing questions
  7. Sources

What 82638 covers

The dibucaine number assay measures the inhibition of plasma butyrylcholinesterase by dibucaine. The result helps characterize atypical enzyme variants that can slow the breakdown of drugs such as succinylcholine and prolong neuromuscular paralysis. Anesthesiologists and other clinicians may order it when a patient has had an unexpectedly prolonged response to these drugs or when an enzyme variant is suspected. Testing is generally performed by a clinical laboratory on a blood-derived specimen.

Report this code for the dibucaine-number assay, not for a general measurement of enzyme activity or a genetic test. Medicare pays it under the CLFS; the 2026 national amount is $12.25 and has remained unchanged since 2020. The amount is the same across states and localities, with no office-versus-facility difference. The test is paid only from the CLFS and has no physician-fee-schedule payment.

This summary was written with AI assistance from CMS Clinical Laboratory Fee Schedule data. Amounts on this page come directly from CMS files.

How Medicare pays 82638

Clinical lab tests aren’t priced like physician services. They’re paid from their own fee schedule, with its own rules. See the whole lab fee schedule.

One national amount

CMS sets a single Clinical Laboratory Fee Schedule amount for 82638. There’s no geographic (GPCI) adjustment, so it pays the same in every state and payment locality.

No office or facility rate

Lab tests aren’t built from relative value units, so there’s no office and facility split: the place of service doesn’t change the CLFS amount.

Updated every quarter

CMS republishes the CLFS each quarter. New tests, often proprietary laboratory analyses (PLA codes), join during the year; existing amounts are updated each January.

Excluded from the physician fee schedule

The physician fee schedule lists 82638 with status X (excluded by statute), so the test itself is paid only from the CLFS.

82638 on the lab fee schedule since 2020

82638 · CLFS 2026 Q4 (current)

$12.25

Unchanged since Jan 1, 2020

Amount in each year’s latest CLFS release · bars start at $0

27 quarterly CLFS releases on file, first CLFS 2020 Q1. A code missing from a quarter wasn’t on that release.

82638 compared with similar tests

82657Enzyme activityNonradioactive substrate$22.17
This code measures dibucaine inhibition of plasma cholinesterase. Code 82657 is for enzyme activity testing in cells, rather than this plasma enzyme phenotype assay.
82658Enzyme activityRadioactive substrate$44.03
This code reports the dibucaine number. Code 82658 concerns enzyme activity testing in cells using a radioactive substrate, a different test method and purpose.

82638 billing questions

When should this code be selected instead of an enzyme activity assay?

Use this code when the laboratory determines dibucaine inhibition to characterize plasma cholinesterase. It is not a general enzyme activity measurement.

Does the dibucaine number measure enzyme quantity?

No. It reflects how strongly dibucaine inhibits the enzyme and helps characterize its phenotype.

Is this a genetic test?

No. It measures dibucaine inhibition of plasma cholinesterase rather than analyzing genetic material.

Is there a separately payable physician interpretation?

Medicare pays this test only under the CLFS; it is excluded from the physician fee schedule.

Does Medicare use a different amount for office and facility testing?

No. The CLFS amount applies nationally, without a locality or office-versus-facility adjustment.

Where this amount comes from

FeeBase reads lab amounts directly from the CMS Clinical Laboratory Fee Schedule file for the quarter: one row per code, with its payment indicator and national amount. Contractor-priced tests are labeled, never given a made-up amount. Amounts are Medicare payment limits, not a patient’s bill or a commercial rate.

CMS CLFS 2026 Q4 · effective Oct 1, 2026 through the day before Jan 1, 2027

Show the CMS file line behind this amount
CLFS row for 82638PUF_CLFS_CY2026_Q4V1.csv, line 1,197 (CLFS 2026 Q4)

Open CMS sourceHow we source rates

Did this answer your question about what Medicare pays for 82638?

Tell us what you were actually trying to work out. We’ll answer you directly, or build the page that does.

Fee sheets · Coming soon

Put 82638 and the rest of your codes on one sheet

Your codes at your locality, with payer contracts beside Medicare.

Join the waitlist